Comparative Pharmacology
Head-to-head clinical analysis: CYSTO CONRAY II versus CYSTOGRAFIN DILUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYSTO CONRAY II versus CYSTOGRAFIN DILUTE.
CYSTO-CONRAY II vs CYSTOGRAFIN DILUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiopaque contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging. It is a high-osmolality ionic monomer that distributes in the extracellular fluid space and is excreted unchanged by glomerular filtration.
Cystografin dilute is a radiocontrast agent containing diatrizoate meglumine, which is an ionic monomeric iodinated compound. It provides radiopacity by absorbing X-rays due to the high atomic number of iodine, allowing visualization of the urinary tract during retrograde cystourethrography. The mechanism is purely physical, with no pharmacological effect.
Intravenous injection or infusion: 50-150 mL of a 282 mgI/mL solution (as sodium iothalamate and meglumine iothalamate) for adults; dose based on procedure and patient size.
Instill 200-300 mL of CYSTOGRAFIN DILUTE (17.2% iodine) via bladder catheter for retrograde cystography. For intraoperative cholangiography, instill 10-25 mL via cystic duct catheter. For voiding cystourethrography (VCUG), fill bladder to capacity (typically 300-500 mL in adults) under gravity until voiding occurs.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged significantly in renal impairment
Terminal elimination half-life: 1–2 hours in normal renal function; prolonged in renal impairment (up to 20–30 hours in severe renal failure)
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <1%
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Iodinated Contrast Agent
Iodinated Contrast Agent